Objectives We evaluated the predictors of recurrent restenosis and the impact of lesion length and vessel size on outcomes in patients treated with routine sirolimus-eluting stent (SES) implantation for in-stent restenosis (ISR) of bare metal stent (BMS).
Methods In this study, 250 consecutive patients with 275 lesions after SES implantation for ISR of BMS were enrolled. Follow-up angiogram was obtained in 239 patients with 258 lesions 8 months after implantation (follow-up rate: 95.6%). We compared characteristics of patients and lesions between the two groups (the recurrent restenosis group and the no-restenosis group).
Results Recurrent restenosis was angiographically documented in 43 lesions (16.7%). Recurrent restenosis was found in 30.4% with small vessel lesions (reference diameter of less than 2.5mm, 92 lesions) and 23% with the diffuse type lesions (106 lesions). Seventy-two percent of patients had a focal pattern of recurrent restenosis. Previously recurrent ISR lesions (odds ratio [OR]: 1.94, 95% confidence interval [CI]: 0.94 to 4.06, p=0.05), reference diameter of less than 2.5mm (OR: 2.41, CI: 1.05 to 5.41, p=0.03), diffuse type restenosis (OR: 4.48, CI: 2.12 to 9.94, p=0.0001) and dialysis patients (OR: 4.72, CI: 1.42 to 15.7, p=0.01) were independent predictors of recurrent restenosis.
Conclusions Small vessels, diffuse type restenosis and dialysis patients were still the predictors of recurrent restenosis in patients treated with SES for ISR of BMS.
- drug eluting stent
- in-stent restenosis
- sirolimus-eluting stent
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.